Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company focused on precision immunotherapy for difficult-to-treat cancers and inflammation, has announced an update to its financial reporting calendar for 2023. The full year 2023 financial statement release and Annual Report, including financial statements, will now be published on March 14, 2024, instead of the previously communicated date of February 29, 2024. The half-year financial report for the period January 1 to June 30, 2023, remains scheduled for August 27, 2024, and the annual general meeting is planned for March 22, 2024.
Following the publication of the full year 2023 financial statement release, a virtual briefing and Q&A session for analysts will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and James O'Brien, Chief Financial Officer, on March 14, 2024, at 3:00 p.m. EET / 1:00 p.m. GMT. The presentation, virtual briefing webcast details, and Annual Report 2023 will be available at www.faron.com/investors. A replay of the analyst briefing will also be made available shortly afterwards.
For more details about the analyst briefing, interested parties can contact [email protected]. Additionally, the company has provided contact information for investor inquiries, including LifeSci Advisors, ICR Consilium, Cairn Financial Advisers LLP, Peel Hunt LLP, and Sisu Partners Oy, the Certified Adviser on Nasdaq First North.
This update provides stakeholders with revised dates for the release of financial statements and the annual general meeting, as well as details about the upcoming analyst briefing and how to access related materials.